TENOXICAM
Pain, Postoperative
Samsun UniversitySmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 81/ 100
Competitive context
31 Active assets in the Pain, Postoperative cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Ataturk University | Phase 4 | BBB |
ROPIVACAINE University of California, Los Angeles | Phase 4 | BBB |
LIDOCAINE Ataturk University | Phase 4 | BBB |
Epinephrine University of California, Los Angeles | Phase 4 | BBB |
NEPENTHE Samsun University | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
TENOXICAM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →